StonvexLoading…
StonvexStonvexStonvexCore line items from MRMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $39.48M | $159.83M | $118.18M | $77.57M |
Operating Income | $125.00K | $-2.82M | $1.71M | $290.00K |
Net Income | $-3.79M | $-14.48M | $-9.85M | $-6.72M |
EPS (Diluted) | $-0.01 | $-0.04 | $-0.03 | $-0.02 |
Total Assets | $201.19M | $202.56M | $205.60M | $204.37M |
Total Liabilities | $147.74M | $137.83M | $136.55M | $131.20M |
Cash & Equivalents | $7.94M | $8.88M | $6.60M | $6.14M |
Free Cash Flow OCF − CapEx | $576.00K | $6.53M | $3.13M | $1.01M |
Shares Outstanding | 398.91M | 396.91M | 394.45M | 392.01M |